What is the appropriate triple therapy regimen for an adult with chronic obstructive pulmonary disease, persistent dyspnea, forced expiratory volume in one second <50% predicted, and a history of at least two moderate or one severe exacerbation in the past year?

Triple Therapy for COPD with High Exacerbation Risk

For an adult with COPD, FEV1 <50% predicted, persistent dyspnea, and ≥2 moderate or ≥1 severe exacerbation in the past year, initiate triple therapy with ICS/LAMA/LABA, preferably as a single-inhaler triple therapy (SITT). 1

Recommended Regimen

Triple inhaled therapy combining an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting β2-agonist (LABA) should be administered as single-inhaler triple therapy rather than multiple inhalers. 1

Specific SITT Options Supported by Evidence:

• Fluticasone furoate 100 μg/umeclidinium 62.5 μg/vilanterol 25 μg once daily via Ellipta inhaler 2
• Budesonide 320 μg or 160 μg/glycopyrrolate 18 μg/formoterol 9.6 μg twice daily 3
• Beclometasone dipropionate 100 μg/formoterol 6 μg/glycopyrronium 12.5 μg (extrafine formulation) twice daily 4, 5

Evidence Supporting Triple Therapy in This Population

The 2023 Canadian Thoracic Society guidelines explicitly recommend LAMA/LABA/ICS triple combination therapy for symptomatic individuals with COPD at high risk of future exacerbations (defined as ≥2 moderate or ≥1 severe exacerbation requiring hospitalization/ED visit in the past year). 1

Exacerbation Reduction Benefits:

• Triple therapy reduces moderate-to-severe exacerbations by 15-25% compared to ICS/LABA and by 23-25% compared to LAMA/LABA. 2, 3, 4
• Severe exacerbations requiring hospitalization are reduced by 34% with triple therapy versus LAMA/LABA alone. 2
• The IMPACT trial demonstrated annual exacerbation rates of 0.91 per year with triple therapy versus 1.07 with ICS/LABA and 1.21 with LAMA/LABA. 2
• The ETHOS trial showed similar benefits with both 320 μg and 160 μg budesonide doses in triple therapy, with 24-25% reduction versus LAMA/LABA. 3

Lung Function Improvements:

• Triple therapy improves pre-dose FEV1 by 61-81 mL compared to LAMA monotherapy at 52 weeks. 5
• Post-dose FEV1 improvements of 117 mL are seen with triple therapy versus ICS/LABA. 2

Why Single-Inhaler Over Multiple-Inhaler Triple Therapy

Single-inhaler triple therapy is strongly preferred because it improves adherence without compromising efficacy. 1

• Adherence improves significantly with SITT, with one study showing complete adherence increasing from 55.8% to 81.7% when switching from multiple inhalers to single inhaler. 6
• SITT demonstrates non-inferiority to multiple-inhaler triple therapy for lung function outcomes while providing superior trough FEV1 improvements. 7
• Exacerbation reduction of 27.56% was observed when switching from multiple-inhaler to single-inhaler triple therapy in real-world practice. 6

Important Safety Considerations

Pneumonia Risk:

The primary harm associated with ICS-containing regimens is increased pneumonia risk, but this is outweighed by exacerbation reduction benefits in high-risk patients. 2, 3

• Pneumonia incidence ranges from 3.5-4.5% with ICS-containing triple therapy versus 2.3% with LAMA/LABA alone. 3
• The hazard ratio for clinician-diagnosed pneumonia with triple therapy versus LAMA/LABA is 1.53 (95% CI 1.22-1.92). 2
• Despite pneumonia risk, net benefit analysis shows a gain of 4.8 quality-adjusted life-years per 100 patients over 20 years with earlier triple therapy initiation in high-risk patients. 8

When NOT to Use Triple Therapy Initially:

• Do not use ICS monotherapy in stable COPD with low exacerbation risk. 1
• For patients with low symptom burden (CAT <10) and mild airflow limitation (FEV1 ≥80%), start with single long-acting bronchodilator instead. 1
• If concomitant asthma is present, ICS/LABA may be preferred as initial dual therapy before escalating to triple therapy. 1, 9

Alternative Pathway if Triple Therapy Fails

If exacerbations persist despite triple therapy in this high-risk patient:

• Add roflumilast if FEV1 <50% predicted and chronic bronchitis is present, particularly if hospitalized for exacerbation in the previous year. 9
• Consider adding azithromycin (macrolide) in former smokers, weighing risk of resistant organisms. 9
• Evaluate for pulmonary rehabilitation, which is recommended for patients in groups B, C, and D (high symptom burden and/or exacerbation risk). 9

Common Pitfalls to Avoid

• Do not delay triple therapy initiation in patients meeting high-risk criteria (FEV1 <50% + ≥2 moderate or ≥1 severe exacerbation), as earlier initiation provides greater net benefit. 8
• Do not prescribe multiple separate inhalers when single-inhaler options are available, as this reduces adherence and real-world effectiveness. 1, 6
• Do not step down from triple therapy to dual therapy in patients with moderate-to-high symptom burden (CAT ≥10) or FEV1 <80% predicted, as guidelines weakly recommend continuation. 1